๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE ยท Real-Time Price ยท USD
1.050
+0.030 (2.94%)
At close: Nov 18, 2026, 4:00 PM EST
1.044
-0.006 (-0.59%)
After-hours: Nov 18, 2026, 6:55 PM EST
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

The off-the-shelf iPSC CAR T platform is positioned for scalable access, with FT819 advancing in lupus nephritis and early autoimmune data showing activity with less intensive or no conditioning. FT839 and FT836 extend development into broader autoimmunity and oncology.

Moderator

Today, it's our pleasure to hear from Bob Valamehr from Fate Therapeutics. I'll hand it to him. Welcome.

Bob Valamehr
President and CEO, Fate Therapeutics

Thank you for the introduction and the presentation here. That I want to give to you, it's very focused on CAR T-cells, and I hope you could appreciate the value that I think that CAR Ts bring to the disease field. This forward-looking statement for your review. I want to take a moment and just talk about CAR T. It's very different. It's transformative in its way that it is traditionally, when you consider conventional drugs, like for example, you can see in the upper panels, an untreated disease expands, grows, and takes over the patient. Conventional drugs, while they have effect, they decay over time. When you take medicine, as we all know, the first amount is the bolus amount, and then it decays over time.

This allows the disease to retract because the medicine is working, but then it relapses because the medicine has now decayed over time. What's very different with a CAR T-cell is that it actually is a living drug, and it reacts to the disease burden, to the disease load. You can see here in the upper right-hand corner, CAR T has a unique ability to overcome the disease and completely eliminate it. You see this in a film on the bottom, and I'm sure you've seen this kind of schematic before, but it's worth reiterating. You can see in the beginning, at the zero hour, there aren't too many cells that are the darker cells, the T-cells that are present in this image series. But over time, you can see that drug, the living drug, reacts to the disease, and it grows, and it expands.

What it's doing that, it actually getting rid of the disease burden. You can see in that video clip how transformative this therapy is, because it's reacting to the disease load, it is eliminating it, then it contracts. We're very excited about this transformative medicine and its application to disease. As we think about that, there's a lot of diseases in autoimmune and oncology that today aren't being treated. The question that I'm putting here in orange is that, is not whether CAR T treatment is coming to rheumatology care, but it is how it's going to get there.

I think there's a lot of conversations right now, whether it's in the oncology field or in rheumatology, about CAR T's and the cost, the safety element, the kind of the delivery of bringing such a unique cell therapy into a world where it's very much comfortable with a pharmacy having that medicine. I hope what I can convey to you in the next 20 minutes is that Fate's off-the-shelf CAR T platform is very unique. It's very differentiated from all others. We have safety in mind, but also patient accessibility in a way that's very much like conventional therapy. There are a lot of words here in these columns, and I will go through what each of these mean in more detail, but it is the unique ability to engineer a cell to be safe by design, but also efficacious by its transformative capabilities.

We have a scalable manufacturing where we can deliver CAR T's in a way that, as I mentioned earlier, traditional medicine is available. This allows us for broad patient access. We administer CAR T's in a way where it's outpatient. You don't have to go through an entire patient burden process to get it. You can just go, get prescribed, and the product will be available. Our pipeline is very much based on innovation, and as I will talk a little about that as well. What I wanted you to take away, if there's anything to take away from my presentation, is that CAR T treatment is coming. It's in oncology now. It'll come to rheumatology. It'll be there for other diseases of inflammation or fibrosis.

It is such a powerful way of handling disease, getting to the disease, that I don't think other therapies, small molecules, mAbs, other biological therapies are just going to be as comprehensive and as thorough as CAR T can be. At the heart of our platform are these iPSC cells. These are induced pluripotent stem cells. The reason we use them is because that if you give them care and give them the love they deserve, they can grow in an unlimited manner. We can engineer a pool of iPSCs, then do a clone selection, and drop individual cells into a 96-well plate, as an example. Let those clones grow. They're now uniform. Each clone has started from a single cell. Compete those clones against each other based on performance, based on molecular attributes.

Select a clone, and that clone now becomes the starting point for your CAR T manufacture. This is very different than any other strategy, because all other strategies engineer at the population level, so you always have heterogeneous population. All other strategies deliver a limited quantity, whether that's patient-derived or donor-derived T-cells, you're limited. Here, this master cell bank concept that's analogous to creation of monoclonal antibodies that's been fundamentally applied for the past 40 years in industry. We have a uniform starting point, and that gives us a unique ability to create an inventory of CAR T-cells and production capacity of CAR T-cells that's unmatched. That gives us unique attributes, because cost of goods are now fundamentally magnitudes less than current CAR T-cells.

We can basically make a CAR T dose at $3,000 per dose at our current inventory level, volume level, and that price will actually get less as our volume increases, and we can increase our volume. Today, our working volume is somewhere in the hundreds of liters, but as we go to tens of, 10,000s of liters and 100,000 L, if we wanted to get to that point, you can simply because the starting material is there for you. In our current capacity, we can make 50,000 CAR T- cells in our current facility. This really creates a unique strategy where you can engineer the cells, make a bunch of CAR T- cells, distribute them globally, and really have an off-the-shelf inventory, very much the foundation that is necessary for broad patient accessibility.

When you think about it, at the heart of it is how disruptive can CAR T- cells be? How disruptive can off-the-shelf CAR T- cells be? We try to create diagrams. It is very hard to capture everything in one slide, but when you compare, and specifically with autoimmune, standard of care therapy compared to T- cell engagers, compared to the CAR T foundation, which includes in vivo CAR T, auto, allo, and FT819, you can see a lot of things start getting resolved as you transition over to an off-the-shelf CAR T- cell. You see safety in mind because of our manufacturing and our engineering practices. You can see meaningful efficacy because it is a CAR T- cell. You can see amazing improvement in quality of life because we are no longer treating patients with CAR T- cells on top of standard of care therapy.

All those steroids, immune suppressants, they go away, they get discontinued. The patient gets to not only appreciate the reduction of symptoms provided by CAR T- cells, but also the fatigue, the brain fog that comes with current standard of care therapy for autoimmune patients is discontinued. They feel great. They feel that they can now get out of bed and go into their normal routine, which is something that we are very proud of. When you think about the need for conditioning chemotherapy, you can see that we are starting to resolve that. When you think about a defined product, you can see how we are different than other CAR T- cells and more similar to traditional biologics. As I mentioned, the scale and the cost, all these things create what we believe is a unique opportunity to drive CAR T- cells into rheumatology care, as I mentioned earlier.

This is our pipeline. We are very proud of it, not just because it is iPSC-derived and gives you that manufacturing inventory scale concept, but also because there is a lot of innovation into these products, as we are capable of putting many engineering attributes into the cell. We have the luxury of doing that, and we have the intelligence and the innovative brain power of the past 15 years coming together and putting together a pipeline that we are very proud of.

I will talk about the RECLAIM, COMPLETE, and PANACEA trials real quickly to give you a perspective on what this pipeline looks like. For autoimmune and FT819, the prevalence of a lot of these diseases in autoimmune is there, and it is very complicated. If you specifically think about lupus, almost every medical show uses lupus as a comedic point to, you have all these problems with you.

I do not know what is going on. Must be lupus. The prevalence is there. Nearly 300,000 patients just in the U.S. have SLE, and with kidney issues, about half of them convert into lupus nephritis. You are really seeing a large population that really needs new therapies. When you look at current therapies, when you think about the primary endpoint for lupus nephritis patients of complete renal response, you can see that a lot of current standard of care therapies fail to give you a one-year response. When you think about currently recently approved add-ons to standard of care therapy, you can also see that in the refractory population, failure continues. There is a unique opportunity to have a CAR T come into lupus nephritis as an entry point and to set the stage for all other autoimmune diseases.

This is where our strategy has come in with a very potent yet safe B- cell depleter, because lupus nephritis is a B- cell disease, and use that as our stepping stone into providing further evidence of why CAR T- cells, and specifically off-the-shelf CAR T- cells, are so unique and can be so transformative in diseases that have unmet need. FT819, as I mentioned earlier, is a CD19-targeting CAR T- cell. It has attributes in it in a uniform way where no other product can have that, and if it is donor or patient-derived. The CAR has been tuned for activity and safety in mind, and there are a lot of different attributes that we have spoken about before. There is a nice publication that summarizes it, but it is a product that uniformly, with safety in mind, can bring this therapeutic revelation or revolution into the picture.

We have treated a good number of patients, as you can see here. More than 35 patients have been treated, and the first point that is so important to us and can be provided through a defined product is the overall safety profile. As you can see here, it is quite favorable. You can see a lot of zeros everywhere. You can see that when you do see a safety outcome. You can see that those are minor, whether it is a grade one or grade two CRS in about 17% of the population. Or when you think about other attributes such as infection rates and cytopenia, you can see those are extremely low as well. This is because we use less intensive conditioning.

We really have come to realize that this patient population is not keen to take three days of intensive chemotherapy, because they are aware of the negative attributes of chemotherapy and steroids, so they shy from it. By giving them the option of seeing good efficacy and combined with reduction of adverse events, this becomes a really nice package for a drug product to be delivered in terms of it has safety and, as I will show, efficacy in mind too. We are very proud of this table. We are very proud that we can deliver this type of medicine to patients in such safe manner. A lot of this is not just the design of the product, but also the way we manufacture it is stable, it is routine. Patient one gets the same product as patient 10, as patient 1,000, and hopefully in the future, patient 10,000.

The other aspect, and this is the fundamental ability of a CAR T- cell, you can see how quick and how sustained the clinical responses are. Whether you're looking at SLEDAI scores, which are composite of symptoms associated with lupus, you can see how dramatically within the first month and subsequently thereafter, you can see the reduction of disease burden. When you look at kidney function, you can also see at the same time such a significant drop in UPCR scores. These trends are real. We've seen it with other CAR T products as well. However, here the uniqueness is that it's delivered from a product that is scaled and available on demand, and the fact that we use less intensive conditioning. Those attributes combined really make this what we believe at Fate the ultimate future for eradicating autoimmune diseases. This is just the beginning.

The translational data really supports what I just showed in the previous slide, where you see deep B-cell depletion. You see deep B-cell depletion in not just the peripheral blood, but also in secondary and tertiary tissues. You also, excuse me, you see the reconstitution of the preferred B-cell state, whether that's reconstitution of the naive state or elimination of the B-cell clones that were most likely resulting in the pathology of the disease. These layers of evidence correspond to the quick and efficacious results that we're seeing, and it's great to see translational data support the clinical outcome. The other point that we really have been talking about, and I hope people start appreciating this, is that all this is happening with discontinued medication. All the standard of care therapy is taken out from day minus five, prior to FT819 introduction.

What you see here that's very different than standard of care therapy is that the patient's symptoms are going away, and they feel great. Most often, and rheumatologists tell us this all the time, the patient tells the physician, Doc, I know you're telling me that my symptoms are improving, but I'm not feeling it. I'm still stuck in bed. What happens here is that those side effects that come with standard of care therapy, because it's discontinued, it's removed. The patient ends up having not just reduction of symptoms, but also improvement of quality of life. You can see that not just in the cartoon, but also in the plot, where patients are going from a state of fatigue to a state of no fatigue over a course of several months. We're very proud of this too.

All this data, the safety, the efficacy, the consistency has given us a unique Sorry, there's a bit of feedback. Maybe I need to stand closer. All these different attributes have given us a good perspective on the fact that this is a real product, this is a real drug, and we should go into the next stage of clinical development. In collaboration with the FDA under RMAT designation and CDRP program inclusion, we have now started our potentially registrational trial in lupus nephritis. As you can see here, it is a single dose of FT819 over a course of six months with a primary endpoint at the six-month duration of complete renal response.

It's a single-arm study, 53 patients, and we believe that this is going to be a foundational study, not just for patients with LN, but also as a first step for Fate to enter a more advanced clinical stage in autoimmune. We're very excited about this because it just sets the stage not just for Fate's success, but also for patient success, and that's what we're most excited about. Other aspects as we tweak the design, as we think about how to move forward, are also looking very promising. Here, we decided that perhaps we can move, as we've already moved away from the need for intense conditioning, perhaps we can move away from conditioning altogether. Here in a clever design, we added FT819 on top of maintenance therapy. What we've seen in the extrarenal lupus side is very encouraging.

You can see here, patient one, two, and three all have responded quite well, and this is without any chemotherapy used. We're excited not just to show that the proof of concept here that we can move away from conditioning chemotherapy, but also it shows that future programs where we're now designing from the beginning not to use conditioning can work in our favor. We're very excited about this data. Two DORIS and one LLDAS. It's quite remarkable when you consider that these patients did not receive any conditioning chemotherapy when FT819 was given to them. The other aspect of our clinical investigation is, because we have the inventory, can we multi-treat, or sorry, multi-dose within a treatment cycle? Here, so we gave two doses to this patient, and we saw a quick drop in disease and improvement in disease score.

That's highlighted here by the patient not only going from a SLEDAI 10 to two within the first month, but achieving LLDAS by the second month. We're quite excited about this approach as well. Because we have the inventory, because we have the cost of goods in our favor, and the on-demand availability in our favor, we can multi-dose within a treatment cycle and be able to perhaps deepen the response or create a longer duration of response. We see very similar results in systemic sclerosis with FT819, so this is not just related specific to lupus. We're very excited about our results. We see that every patient is achieving an rCRISS of 25 or better, so this is again another composite score of disease symptoms. Skin scores are improving dramatically, and we're looking forward to providing an update on the advancement of this trial as well.

Really quickly, FT839. The reason we started thinking about FT839 is because autoimmune disease is beyond, most of them are beyond just B- cells driven. While lupus, there's a lot of evidence that it is mainly a B- cell disease, other diseases such as RA, rheumatoid arthritis, have a multicellular component to their pathology. There's a T- cell component, a myeloid macrophage component to it. We came up with a product that can, a CAR T product that can go after, in a comprehensive way, after all activated and aberrant immune cells. That product is FT839, as I mentioned earlier, and this is a complicated plot, but when you look at the bottom, and I'll just take you quickly to the bottom right-hand corner, you can see that FT839, it's not like chemo where it gets rid of all the immune cells.

It actually just goes after the activated components of the immune cells. Those cells in your body that are the T- cells, the NK cells that you need to fight infection and get rid of the starting point of cancer, those are resting because you're not actively fighting something. But those cells that are activated because of your pathology and autoimmune are eliminated. Here, while FT819 was a great product for a B- cell driven reset, here would be an immune cell-driven reset, where we can now get rid of inflammation, get rid of the aberrant activated cells, and allow the patient to have a complete immune reset, whether that's B- cells, T- cells, and so on. Very excited about FT839, the unique targeting of CD19 and CD38 at the same time.

That has led to the COMPLETE trial where we are actively recruiting patients, activating sites, and we look forward to giving you an update on this as well early next year. But this product, if it works, it really creates an entry point into comprehensive elimination of aberrant cells that are multicellular. We're going after a disease state, not just a disease lineage, and we're very excited about the outcomes. Because of the additional engineering attributes, we're moving into this trial without the need of any conditioning chemotherapy, which I think that really solves another challenge that CAR T is facing. Again, as I mentioned earlier with FT819, the evidence is there for this to work and be successful. I'll really quickly talk about oncology. Oncology also has a massive unmet need. The disease in oncology is one that quickly, through clonal repopulation, escapes the treatment therapy.

There, it is nearly impossible to think that I'm going to block a single signaling cascade in oncology and not remember that cancer is super intelligent and will just find the other 20,000 signaling mechanisms that are in the body to survive. So we need something that goes after the heart of the disease, not just from a key aspect. We've developed FT836, where it goes after what biology has given or has blessed a cell with. That's, if you're in a disease state, go ahead and put some stress antigens on your surface. That's inherent biology.

Cancer has been smart and says, well, if this cell is going to put some red flags on top of it, I'm going to cut it off. But our CAR T- cells are resistant to that cleavage of the red flag of the stress antigen and target the disease independent of that escape mechanism. When you think about all the cancers that you're going after, you actually end up seeing that nearly every cancer is susceptible to targeting by FT836. We've talked about some patient cases where in colorectal cancer, we've seen reduction of disease. We've seen the target lesions drop, and this is without the use of any conditioning chemotherapy, which again tells us that our approach into designing molecular attributes, gene edits, to avoid the need of conditioning is working.

Because in oncology, where CAR T- cells come in with intensive conditioning to create space, to create ability to proliferate. We've been able to engineer ourselves into avoiding the need for conditioning, but still having the attributes of growth and efficacy of a CAR T-cell. We're very excited about this. Just a quick note to the persistence, you can see that the product is there in blood for the first two weeks in the lower left-hand side. Most importantly, we saw the product in the tumor at day 22 as well. The product is there, it's going where it's supposed to go, and it's doing its job, and we're very excited of giving you an update on this as well in the PANACEA trial. I'll stop here.

There's a lot of stuff to look forward to over the course of the next 14 months, advancing RECLAIM-LN, exploring FT819 in systemic sclerosis and extrarenal lupus, developing FT839 in not just RA, but in multiple autoimmune diseases that we think has large prevalence in general, a huge unmet need, progressing FT836 in CAR-NK in oncology. We have the financial strength to do this, so we're very excited about what's coming up in our near future, and I'm happy to answer questions. Thank you. Ex vivo, yes. There is no in vivo component here.

Moderator

Are you planning to do any?

Bob Valamehr
President and CEO, Fate Therapeutics

No. Thank you for giving me the opportunity to talk about in vivo. As a scientist of 20 years in a TC room, I cannot imagine how you would control in vivo engineering. I would try to engineer a cell on Tuesday, and the same cell gives me a different outcome on Wednesday. How can you control what happens in the body?

We think in vivo engineering is very complicated, and I tip my hat to those who want to try to control it. Knowing the potency of a CAR T and the stochastic chaos that you could bring into in vivo engineering, it's not something that we're pursuing currently. We have a very defined platform that overcomes the need for any value point that in vivo would bring to the table. We have it here, but we're defined, and we're controlled. For us, it doesn't make sense to go down the in vivo path. Thank you for the question.

Moderator

Thank you. That sounds like we got to finish. Thank you, everyone.